Source: Virtual Congress 2021 – Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease?



Rating:

Share or cite this content

Citations should be made in the following way:
S. Tomassetti (Florence, Italy). Use of antifibrotics in post-COVID ILD: CON. Virtual Congress 2021 – Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease?

Member's Comments

No comment yet.

Related content which might interest you: Use of antifibrotics in post-COVID ILD: PRO Source: Virtual Congress 2021 – Post COVID interstitial lung diseases syndrome: diagnosis and management as interstitial lung disease? Year: 2021 Use of Decametoxinum in bronchiectasis Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Late Breaking Abstract - Use of a simple telecoaching pulmonary rehabilitation protocol for COPD patients. Source: International Congress 2019 – Breathing, posture and physical activity in respiratory disease patients Year: 2019 Inspiration: An assistance program for idiopathic pulmonary fibrosis patients on pirfenidone Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Idiopathic pulmonary fibrosis treatment: Combined pirfenidone + acetylcysteine vs N-acetylcysteine in monotherapy Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Use of alternative therapies in patients with asthma and COPD: is there any difference? Source: Eur Respir J 2005; 26: Suppl. 49, 504s Year: 2005 Benefits of pulmonary rehabilitation on ILD patients: a comparison between two types of training Source: International Congress 2018 – Let’s interact and discuss the hot topics in pulmonary rehabilitation Year: 2018 Treatment of advanced homogenous emphysema with endobronchial coils compared to NETT subjects who received LVRS or medical therapy Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Use of pulse oximetry to select who should be screened for long term oxygen therapy (LTOT) in interstitial lung disease (ILD) patients Source: International Congress 2014 – Best posters in chronic care Year: 2014 Late Breaking Abstract - Safety of combined pirfenidone (PFD) and nintedanib (NIN) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Late-breaking findings in pulmonary diseases Year: 2017 Exercise training in patients with interstitial lung disease (ILD): Can reponders be distinguished from non-responders Source: International Congress 2015 – Effects of rehabilitation, exercise, physical activity, hospitalisation and surgery on different conditions Year: 2015 COPD patients' expectations of ICS/LABA therapy Source: International Congress 2014 – Management of COPD in primary care Year: 2014 Use of Rituximab in the treatment of CTD-ILD in RA patients. Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Use of surfactant-BL (S-BL) in complex treatment of pulmonary TB patients Source: Eur Respir J 2003; 22: Suppl. 45, 521s Year: 2003 Tolerance of pirfenidone in Indian patients with idiopathic pulmonary fibrosis – Usual interstial pneumonitis: An initial experience Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition Source: International Congress 2018 – New methods for diagnosing and treating lung diseases Year: 2018 MUSIC: Efficacy and safety of macitentan in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Effectiveness of indacaterol with or without tiotropium in patients with moderate or severe chronic obstructive pulmonary disease (COPD) - the GOLDEN II study Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care Year: 2014 Safety and efficacy of emphysematous lung sealant (ELS) therapy for advanced emphysema out to 2 years Source: Annual Congress 2013 –Bronchoscopic treatment of COPD and asthma: where are we going? Year: 2013